Factors associated with the development of HIV associated lipodystrophy in patients on long-term HAART
Kayima, Joshua K
Otieno, Fredrick C F
McLigeyo, Angela A
MetadataShow full item record
Highly active antiretroviral therapy is effective in reducing viral load and increasing survival in HIV-1infected patients. It consists of two nucleoside reverse transcriptase inhibitors and a protease inhibitor or two nucleoside reverse transcriptase inhibitors and a non-nucleoside reverse transcriptase inhibitor. The efficacy of Highly active anti-retroviral therapy (HAART) is however compromised by adverse events such as lipodystrophy in patients on long-term HAART. This study was carried out in 265 HIV-1 seropositive patients treated with HAART for 6 months and longer, in order to correlate patients’ age, gender, CD4 counts, WHO stage at initiation of HAART, duration and type of anti-retroviral therapy with development of lipodystrophy. A longer duration of therapy was found to be significantly associated with the development of lipodystrophy with 19 patients (24.7%), 73 patients (60.8%) (OR 2.06; CI 1.21 to 3.51, p value 0.004) and 39 patients (67.2%) (OR 2.34; CI 1.21 to 1.46, p value 0.006) having lipodystrophy at 6 to 18, 18 to 36 and 36 to 72 months of treatment, respectively. The odds of lipodystrophy after HAART for 18 to 36 months and 36 to 72 months was 4.14 (p < 0.0001) and 6.179 (p < 0.0001) times, respectively, higher than after HAART for 6 to 18 months. There was no association between age, gender, CD4 counts, WHO stage and the development of lipodystrophy.
CitationMcLigeyo, Angela Awino, Godfrey Lule, Fredrick CF Otieno, Joshua Kyateesa Kayima, and Enoch Omonge. "Factors associated with the development of HIV associated lipodystrophy in patients on long-term HAART." Journal of AIDS and 5, no. 12 (2012): 448-454.
- Faculty of Health Sciences (FHS)